Risk factors for osteoporotic fracture include (but are not limited to) increasing age, female sex, postmenopause for women, hypogonadism or premature ovarian failure, low body weight, history of parental hip fracture, ethnic background (white persons are at higher risk than black persons), previous clinical or morphometric vertebral fracture, previous fracture due to minimal trauma (that is, previous osteoporotic fracture), rheumatoid arthritis, current smoking, alcohol intake (3 or more drinks daily), low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, falling, and immobilization (5) . Another risk factor for osteoporotic fracture is long-term use of certain medications, the most commonly implicated being glucocorticoids, anticoagulants, anticonvulsants, aromatase inhibitors, cancer chemotherapeutic drugs, and gonadotropin-releasing hormone agonists (5) .
Osteoporosis can be diagnosed by the occurrence of fragility fracture. In patients without fragility fracture, osteoporosis is often diagnosed by low BMD. Dualenergy x-ray absorptiometry (DXA) is the current gold standard test for diagnosing osteoporosis in people without an osteoporotic fracture. Results of DXA are scored as SDs from a young, healthy norm (usually female) and reported as T scores. For example, a T score of -2 indicates a BMD that is 2 SDs below the comparative norm. The international reference standard for the description of osteoporosis in postmenopausal women and in men aged 50 years or older is a femoral neck BMD of 2.5 SD or more below the young female adult mean (2) . Low BMD as measured by DXA is an imperfect predictor of fracture risk, identifying less than one half of the people who go on to have an osteoporotic fracture.
Bone density can also be classified according to the Z score, the number of SD above or below the expected BMD for the patient's age and sex. A Z score of -2.0 or lower is defined as either "low BMD for chronological age" or "below the expected range for age," and those above -2.0 are "within the expected range for age" (6) . Risk scores that combine clinical risk factors with BMD testing results, such as FRAX (the World Health Organization Fracture Risk Assessment Tool), can be used to predict fracture risk among people with low bone density.
Pharmacologic treatments for osteoporosis include bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), peptide hormones (teriparatide [the 1,3,4 amino acid fragment of parathyroid hormone] and calcitonin), estrogen (in the form of menopausal hormone therapy) for postmenopausal women, and selective estrogen receptor modulators (SERMs) (raloxifene for postmenopausal women). Most of the treatments aim to prevent bone resorption. Denosumab (a new biologic agent), dietary and supplemental calcium, and vitamin D are also used for treatment. Bazedoxifene, a SERM, has recently been approved by the U.S. Food and Drug Administration (FDA) with conjugated estrogen for prevention of osteoporosis.
GUIDELINE FOCUS AND TARGET POPULATION
This updated guideline presents additional available evidence on treatments, including new medications and biologic agents, to prevent fractures in men and women with low bone density or osteoporosis since publication of the ACP 2008 guideline, and replaces the 2008 guideline (7) . Several therapies included in the 2008 guideline have been excluded from the update, including calcitonin, which is no longer widely used for osteoporosis treatment, and both etidronate and pamidronate, neither of which are FDAapproved for the prevention of fractures or treatment of osteoporosis. One new biologic, denosumab, a human monoclonal antibody approved by the FDA for treatment of osteoporosis, has been added since publication of the 2008 guideline. Different medications for the treatment of osteoporosis may affect various parts of the skeletal system differently. The target audience for this guideline includes all clinicians and the target patient population includes men and women with low bone density and osteoporosis. These recommendations are based on a systematic evidence review sponsored by the Agency for Healthcare Research and Quality (AHRQ) (6, 8) . This guideline is endorsed by the American Academy of Family Physicians.
METHODS

Systematic Review of the Evidence
The evidence review was conducted by AHRQ's Southern California Evidence-based Practice Center-RAND Corporation. Appendix 1 (available at Annals .org) summarizes the methods for the evidence review, and additional details can be found in the reports (6, 8) .
Reviewers searched databases from 2 January 2005 to 3 June 2011. A machine-learning method was used to update the searches, once in 2014 and then specifically on bisphosphonates, calcium, vitamin D, and estrogen through 12 July 2016 (9). Appendix 2 (available at Annals.org) shows the search methodology for the update. Reviewers also did a limited search on the recently FDA-approved drug bazedoxifene from 1 January 2013 to 26 October 2016. Evidence tables for studies identified in the 2016 update search are 
BENEFITS OF TREATMENT FOR FRACTURE RISK REDUCTION IN INDIVIDUALS WITH DIFFERENT FRACTURE RISKS Bone Mineral Density
Moderate-quality evidence from post hoc analysis of 1 RCT showed that low femoral neck BMD did not predict the effect of alendronate on clinical vertebral or nonvertebral fracture risk (240) .
FRAX Risk Assessment
Moderate-quality evidence from post hoc analysis of 1 RCT showed no significant interaction between fracture risk as assessed by FRAX and the efficacy of raloxifene for reducing the relative risk for vertebral fractures in women older than 75 years (241) .
Prior Fractures (Prevention vs. Treatment)
Evidence is insufficient for prevalent fractures to predict the efficacy of alendronate or raloxifene treatment in reducing risk for fractures in postmenopausal women, because studies reported conflicting results (240, (242) (243) (244) . Moderate-quality evidence from post hoc analysis of 1 RCT showed that postmenopausal women with prevalent vertebral fractures benefited more from teriparatide treatment than those without prevalent fractures (245) .
Age
High-quality evidence showed that bisphosphonates and teriparatide are at least as effective for older patients as they are for younger patients (246 -249) .
Sex
Evidence is insufficient regarding the effectiveness of therapies to prevent fractures or treat osteoporosis in men, because few relevant studies have been published (28, 50 -52, 82, 90, 136, 157, 166) . Two RCTs evaluated vitamin D treatment in men and women and reported on fractures (136, 166). One study showed that calcium plus vitamin D 3 reduced the risk for fracture among elderly women but not elderly men (136). The other study showed no difference in fracture reduction for elderly men treated with intramuscular injection of ergocalciferol, whereas women had increased risk for wrist fractures (166).
Race/Ethnicity
High-quality evidence from post hoc analysis of 2 RCTs showed that compared with placebo, raloxifene decreases the relative risk for vertebral fracture but not nonvertebral or hip fracture among Asian women (250), consistent with findings from U.S. studies.
Glucocorticoid Treatment
Moderate-quality evidence showed that alendronate, risedronate, and teriparatide reduced fracture risk in patients taking glucocorticoids (30, 219) .
Renal Insufficiency
Evidence is insufficient from trials assessing the effect of renal function on the efficacy of alendronate, raloxifene, and teriparatide in preventing fractures in osteoporotic women (251) (252) (253) (254) .
HARMS OF PHARMACOLOGIC TREATMENT FOR REDUCING FRACTURES Bisphosphonates
Low-quality evidence showed that bisphosphonates are associated with atypical subtrochanteric fractures, and the FDA has issued a warning for these drugs (255) . Evidence suggests that this adverse event may be related to treatment duration, because the rate of atypical fractures for women taking bisphosphonates for less than 2 years was 1.78 per 100 000 and increased to over 100 per 100 000 in women taking the drugs for 8 years or more (256) .
Low-quality evidence also showed that bisphosphonates are associated with osteonecrosis of the jaw, although this side effect is rare .
The 2008 guideline reported that bisphosphonates may be associated with atrial fibrillation; however, most new evidence suggests that there is no increased risk (126, [283] [284] [285] [286] [287] [288] . A recent post hoc double-blind extension of the HORIZON-PFT trial found no difference in atrial fibrillation with 9 years versus 6 years of treatment with zoledronic acid in osteoporotic postmenopausal women, although women treated for 9 years had a higher incidence of any arrhythmia (14.1% vs. 4.2%; P = 0.02) (85) . One study showed that bisphosphonates were associated with increased risk for incident acute myocardial infarction (hazard ratio [HR], 1.38 [95% CI, 1.08 to 1.77], after cardiovascular disease risk factors were controlled for) after a median 3.6 years of follow-up (289) . A population-based cohort study also showed that bisphosphonates were associated with increased risk for cardiovascular events, including atrial fibrillation (adjusted HR, 1.55 [CI, 1.04 to 2.39]) and congestive heart failure (adjusted HR, 1.65 [CI, 1.36 to 1.99]) (290) . In contrast, a recent meta-analysis concluded that there is no significant association between oral or intravenous bisphosphonate use and total cardiovascular events, stroke, myocardial infarction, or cardiovascular death (287) .
High-quality evidence showed that bisphosphonates are associated with mild upper gastrointestinal symptoms (83, [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] , and a network meta-analysis did not show statistically significant differences between the various bisphosphonates for gastrointestinal symptoms (304).
High-quality evidence showed that zoledronic acid is associated with hypocalcemia (odds ratio [OR], 7.22 [CI, 1.81 to 42.7]) (81, 305) . High-quality evidence also showed that zoledronic acid is associated with influenza-like symptoms (OR, 6.39 [CI, 5.76 to 7.09]) (79, 81, 82, 306 -308) . A recent secondary analysis of a double-blind RCT showed an increased incidence of uveitis (1.1% [CI, 0.5% to 2.1%]) and episcleritis (0.1% [CI, 0.0% to 0.7%]) in women treated with zoledronic acid (309) .
Ibandronate is associated with myalgias, cramps, and limb pain (OR, 2.25 [CI, 1.57 to 3.29]) (92, 310) , and zoledronic acid is associated with adverse effects including atrial fibrillation (OR, Evidence is insufficient to associate bisphosphonates with increased cancer risk, because studies report conflicting results (292, [311] [312] [313] [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] .
Denosumab
High-quality evidence showed that denosumab is associated with mild upper gastrointestinal symptoms (OR, 1.74 [CI, 1.29 to 2.38]) (43, 327) . Moderate-quality evidence showed that denosumab is associated with increased risk for infection (risk ratio [RR], 1.26 [CI, 1.01 to 1.57]) (328) . One small RCT reported a slight increase in bacterial cellulitis with patients treated with denosumab compared with placebo (1.3% vs. 0.6%), but no increase in serious infection (1.1% vs. 1.5%) (109) . Denosumab has also been associated with rash/ eczema (OR, 1.96 [CI, 1.46 to 2.66]) (43, 96, 97) . A post hoc analysis of the open-label extension of FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months) confirmed 2 events of atypical femoral fracture and 8 events of osteonecrosis of the jaw through 8 years of denosumab therapy (100) .
Teriparatide
High-quality evidence showed that teriparatide is associated with mild upper gastrointestinal symptoms (OR, 3.26 [CI, 2.82 to 3.78]) (113, 117, 329, 330) (254) . There were no incident cases of osteosarcoma associated with use of this medication in the first 4 years of the voluntary Forteo Patient Registry safety study (333) , and in a postmarketing case series study encompassing 9 years of osteosarcoma cases, no patient reported use of teriparatide before diagnosis of osteosarcoma (334) .
SERMs
High-quality evidence showed that raloxifene is associated with hot flashes (OR, 1.58 [CI, 1.35 to 1.84]) (122, 123, (335) (336) (337) (338) (339) (340) and thromboembolic events (OR, 1.63 [CI, 1.36 to 1.98]) (122, 336, (341) (342) (343) (344) (345) (346) . Raloxifene is also associated with pulmonary embolism (OR, 1.82 [CI, 1.16 to 2.92) (122, 341, 345, 347) and cerebrovascular death (OR, 1.56 [CI, 1.04 to 2.39]) (122, 341, 342, 348 -350) . A study comparing postmarketing surveillance of raloxifene in younger women (aged <75 y) versus older women (aged ≥75 y) showed no difference in overall adverse effects from raloxifene (351) .
Estrogen Therapy for Postmenopausal Women
High-quality evidence from the Women's Health Initiative showed that menopausal hormone therapy was associated with increased risk for cerebrovascular accidents and venous thromboembolic events (7, 352). One subsequent assessment of the trial showed that the higher incidence of breast cancer decreased after therapy was discontinued (353) . Another study showed that estrogen plus progestin therapy was associated with more invasive breast cancer, more node-positive tumors, and more deaths due to breast cancer than placebo (354).
Calcium and Vitamin D
Although previous data suggested an association between calcium supplementation and increased risk for myocardial infarction, moderate-quality evidence shows no association (355) . One study showed increased risk for hypercalciuria with vitamin D supplementation (356) .
MONITORING OF PATIENTS WITH OSTEOPOROSIS
There is no evidence from RCTs regarding how often to monitor BMD during osteoporosis treatment. Moderate-quality evidence suggests that most women do not need regular monitoring (357) (358) (359) (360) (361) (362) (363) (364) (365) (366) (367) (368) . Data from 1 study (365) showed that only 10% of women with normal or mildly osteopenic DXA scores (T score > -1.49) develop osteoporosis within 15 years; 10% of women with moderate osteopenia (T score, -1.50 to -1.99) develop osteoporosis within 5 years; and 10% of women with advanced osteopenia (T score, -2.0 to -2.49) develop osteoporosis within 1 year. Another study showed no improvement in prediction of hip or major fractures in women who had BMD measured 4 years after baseline (357) . Overall data from several studies (358 -363) showed that women treated with antiresorptive treatment (including bisphosphonates, raloxifene, and teriparatide) benefited from reduced fractures with treatment even if BMD did not increase.
DURATION OF PHARMACOLOGIC THERAPY
Low-quality evidence showed that the appropriate duration of treatment is uncertain, although high-risk patients may benefit from more than 5 years of treatment (240, 242, 369 -371) . One study showed no cumulative difference in the risk for nonvertebral fractures in women continuing alendronate therapy for 5 versus 10 years (18.9% vs. 19%) (240) . Post hoc analysis of this study showed that women with femoral neck T scores of -2.5 or worse and baseline prevalent vertebral fracture had reduced fracture risk by continuing alendronate therapy for 10 years versus stopping after 5 years compared with placebo (11.1% to 5.3%) (242) . Another study on zoledronic acid showed no difference for clinical vertebral fractures, hip fractures, nonvertebral fractures, or all clinical fractures in women who continued to receive the drug for 3 versus 6 years (369).
The 
FUTURE RESEARCH
Most of the evidence for treating osteoporotic men is based on trials that included women, and further research is needed on the treatment of men. Studies directly addressing the efficacy of pharmacologic treatments for reducing fractures in patients with osteopenia are also needed. 
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RECOMMENDATIONS
Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence)
High-quality evidence showed that pharmacologic treatment in postmenopausal women who have osteoporosis (T scores ≤ -2.5 or those who have experienced fragility fractures) is beneficial for preventing further bone loss and reducing the risk for initial or subsequent fractures. Some bisphosphonates (alendronate, risedronate, and zoledronic acid) and the newer biologic agent denosumab reduce radiographic vertebral as well as clinical, nonvertebral, and hip fractures.
Both bisphosphonates and denosumab are associated with mild gastrointestinal symptoms. Denosumab is also associated with increased risk for infection and rash or eczema. Bisphosphonates are associated with atypical subtrochanteric fractures and osteonecrosis of the jaw. Although there is no association between bisphosphonates and atrial fibrillation, some studies have reported increased cardiovascular events. Zoledronic acid is associated with hypocalcemia, influenza-like symptoms, arthritis and arthralgias, headache, and uveitis.
When prescribing bisphosphonates, clinicians should discuss the importance of adherence. Factors associated with poor adherence include side effects and the inconvenience of taking medications, absence of symptoms for underlying disease, comorbid conditions, age, and socioeconomic status.
Although evidence showed that raloxifene and ibandronate reduce radiographic vertebral fractures, and teriparatide reduces vertebral and nonvertebral fractures, studies have shown no benefit for these drugs to reduce all fracture types; therefore, they are not recommended as a first-line pharmacologic treatment. Raloxifene is associated with serious harms, such as thromboembolism. Calcitonin, which is no longer widely used for osteoporosis treatment, was not considered in this guideline.
Calcium and vitamin D may be added as dietary supplements to osteoporosis treatment regimens, although the effectiveness of these regimens on fracture prevention is unclear. The majority of trials with bisphosphonate therapy gave women calcium supplements and many also gave vitamin D; therefore, supplementation with these agents may be considered. However, dosages should be carefully considered, because excess dosing has been associated with hypercalcemia (221, (372) (373) (374) (375) (376) (377) . Moderate-quality evidence showed no association between calcium supplementation and increased risk for myocardial infarction (355) , but a large trial demonstrated an increase in kidney stones (137).
Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence)
Although the direct evidence is insufficient to determine the appropriate duration of pharmacologic therapy, most studies that evaluated the benefit of treatment continued therapy for up to 5 years. Continuing treatment after the initial 5 years may be beneficial for some patients and may be appropriate after reassessing the risks and benefits of continuing therapy. Post hoc analysis from an RCT (242) suggested that patients treated with alendronate who had preexisting fractures or those with a BMD of -2.5 or less after 5 years of initial therapy may benefit from continued treatment, because these patients experienced a decreased incidence of new clinical vertebral fractures.
Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence)
Data that specifically apply to men are sparse. However, no evidence suggests that outcomes associated with pharmacologic treatment would differ between men and women if based on similar BMDs. Data for men are extrapolated from studies that included women with T scores of -2.5 or less or those who have experienced fragility fractures. Moderate-quality evidence from 1 study that detected fractures radiographically showed that zoledronic acid reduced vertebral fractures in osteoporotic men (95) . In women, some bisphosphonates (alendronate, risedronate, and zoledronic acid) reduce vertebral, nonvertebral, and hip fractures. The overall quality of evidence was downgraded to low owing to indirectness. Bisphosphonates are associated with adverse effects, including mild gastrointestinal symptoms, atypical subtrochanteric fractures, and osteonecrosis of the jaw.
Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence)
Current evidence does not show any benefit for bone density monitoring during treatment. Moderatequality evidence showed that women treated with antiresorptive treatment (including bisphosphonates, raloxifene, and teriparatide) benefited from reduced fractures with treatment, even if there was no increase in BMD or if BMD decreased. There was no evidence for BMD monitoring for men.
Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence)
Moderate-quality evidence showed that menopausal estrogen treatment did not reduce fracture risk in postmenopausal women with established osteoporosis. Evidence from a previous systematic review (131) showed that estrogen decreased fracture risk; however, many of these studies focused on postmenopausal women with low bone density, or on postmenopausal women in general rather than those with established osteoporosis. Estrogen treatment is associ-
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ated with serious harms, such as increased risk for cerebrovascular accidents and venous thromboembolism, and these harms significantly outweigh the potential benefits. Although raloxifene has some benefit in reducing vertebral fractures, it does not reduce hip fracture or nonvertebral fractures and is associated with serious harms, including thromboembolism.
Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence)
Low-quality evidence showed that treatment with risedronate in women with osteopenia (defined as a T score of -1.0 to -2.5) near the osteoporosis threshold (T score of -2.5) may reduce their fracture risk. This evidence comes from a post hoc analysis of 2-year follow-up data from 4 large RCTs of postmenopausal women with advanced osteopenia and no prevalent vertebral fractures that showed that treatment with risedronate significantly reduced the risk for fragility fracture compared with placebo (73% lower than placebo) (378) . This effect is similar to fracture reductions seen in women with osteoporosis undergoing the similar treatment. Duration of treatment in these studies was 1.5 to 3 years.
Although the current evidence is limited to a post hoc evaluation of risedronate in women with advanced osteopenia, the CGC believes that the benefit of fracture reduction is likely to be similar across all bisphosphonates, on the basis of data in osteoporotic women. However, the efficacy of other bisphosphonates has not been directly evaluated in osteopenic women, and no study has been conducted to primarily assess the effects of fracture prevention in women with osteopenia.
The rate of progressive bone loss and the risk for fracture range widely across the osteopenic spectrum and according to additional factors, such as age. The risk for severe adverse effects increases with prolonged use of bisphosphonates. Given the limited evidence supporting benefit, the balance of benefits and harms of treating osteopenic women is most favorable when the risk for fracture is high. Women younger than 65 years with osteopenia and women older than 65 years with mild osteopenia (T score between -1.0 and -1.5) will benefit less than women 65 years of age or older with severe osteopenia (T score < -2.0).
Clinicians can use their own judgment based on risk factors for fracture, or they can use a risk assessment tool. Several risk assessment tools, such as FRAX (World Health Organization Fracture Risk Assessment Tool), are available to predict fracture risk among untreated people with low bone density (379). Although FRAX is widely used, there is no evidence from RCTs demonstrating a benefit of fracture reduction when FRAX scores are used for treatment decision making. Factors that increase the risk for fracture in women include lower body weight, smoking, weight loss, family history of fractures, decreased physical activity, alcohol or caffeine use, low calcium and vitamin D intake, and corticosteroid use (7, 380, 381).
INCONCLUSIVE AREAS OF EVIDENCE
Comparative effectiveness trials evaluating pharmacologic treatments for low bone density or osteoporosis are lacking. In addition, although FRAX scores are widely used, evidence linking FRAX scores to treatment efficacy is lacking. One post hoc analysis of a trial with raloxifene showed that treatment efficacy did not vary according to FRAX score (241) , and at age 75 years, the risk reduction for vertebral fracture was similar across FRAX scores.
HIGH-VALUE CARE
The current evidence does not support frequent monitoring of women with normal bone density for osteoporosis, because data showed that most women with normal DXA scores did not progress to osteoporosis within 15 years. The data also do not support monitoring BMD during the initial 5 years of treatment in patients receiving pharmacologic agents to treat osteoporosis. Clinicians should select generic drugs to treat osteoporotic patients when possible ( Table 2) . are not intended to override clinicians' judgment. All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.
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Search Strategy
The literature search included identified trials published in the English language by searching MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, the American College of Physicians Journal Club database, the National Institute of Clinical Excellence, the NHA Technology Assessment Program, the FDA's MedWatch database, and relevant pharmacologic databases from 2 January 2005 to 3 June 2011 and was updated to March 2014 by using a machine-learning method (9). Evidence was further updated specifically for bisphosphonates, calcium, vitamin D, and estrogen through 12 July 2016. Reviewers also did a limited search on the recently FDA-approved drug bazedoxifene from 1 January 2013 to 26 October 2016 (see Appendix 2 for the search strategy). Only RCTs and published systematic reviews of RCTs that met inclusion criteria were included in the assessment of effectiveness. Where no RCTs were available, large observational studies (with more than 1000 participants), systematic reviews, and case reports (for rare events) were included (for example, assessment of effects in subgroups or assessment of particular serious adverse events).
Quality Assessment
The quality of RCTs, observational studies, and meta-analyses was assessed by using the Jadad scale, the Newcastle-Ottawa Scale, and the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) criteria, respectively (383) (384) (385) . The overall quality of evidence and strength of recommendations was graded according to ACPs' clinical practice guidelines grading system (10).
Population
Studies were limited to those conducted in adults older than 18 years, healthy adults, those with low bone density, or those with osteoporosis.
Interventions Evaluated
Pharmacologic agents approved for use in the United States including bisphosphonates (alendronate, risedronate, ibandronate, and zoledronic acid), teri-paratide, raloxifene, and menopausal estrogen therapy; the biologic agent denosumab; dietary and supplemental calcium and vitamin D; and physical activity.
Comparators
The efficacy or effectiveness of the intervention in question were compared with that of placebo or another potency or dosing schedule for the same agent or another agent in the same or another class.
Outcomes
Outcomes evaluated include reduction in fracture (total, vertebral, nonvertebral, spine, hip, wrist, other) and adverse events.
Target Audience
The target audience for this guideline is all clinicians.
Target Patient Population
The target patient population is all adult men and women with low bone density or osteoporosis.
Peer Review
The AHRQ systematic review was peer-reviewed and posted on the AHRQ website for public comments. The 2014 evidence reviews also underwent a peer review process through the journal. The guideline underwent a peer review process through the journal and was posted online for comments from ACP Regents and ACP Governors, who represent physician members at the national and international level.
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